Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Newly Merged Wholesaler Koyo to Get No. 3 Share in Shikoku
April 1, 2002
- 26th JMC General Assembly to Invite Citizens to Participate
April 1, 2002
- Yamanouchi Ties Up with Metabolex for Discovering Diabetes Drugs
April 1, 2002
- Nikken Chemicals to Focus on Drugs
April 1, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 1, 2002
- NTT DATA to Provide Free Software for Compressing Genome Data
March 25, 2002
- FDA Approves Gen-Probe's HIV-1, HCV Blood Screening Test
March 25, 2002
- Pharmagene Forms Its First Indication Switch Alliance with Sosei
March 25, 2002
- NHI Price Revision to Hit Companies Differently
March 25, 2002
- Takara Sets Up Target Protein Mass Production System in Tandem with UMDNJ
March 25, 2002
- Sales of Lipitor Increase by 216% to \40 Bil.: Mr Bootes of Pfizer
March 25, 2002
- Kyowa Hakko Discovers New Type of Mesenchymal Stem Cell
March 25, 2002
- Kyorin Europe Starts Operations in Germany
March 25, 2002
- Bungyo Rate Up 4.8 Points to 45.5%
March 25, 2002
- Revision of Medical Fees to Change Outpatients Visiting Pattern
March 25, 2002
- Cost Calculation Method Needs Improvements: Dr Sugaya of JMA
March 25, 2002
- Operation of Hospitals by Profit-making Organizations Not Recommended
March 25, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 25, 2002
- Speed of Clinical Trials up to 18 Times Slower in Japan: Korosho
March 25, 2002
- Franchise Business GL Proposed by FTC
March 25, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…